Hematopathology Practice Questions

Q: A patient presents with bleeding due to platelet function defects. Which of the following features is typically observed?

Normal platelet count and increased bleeding time. **Explanation:** The core concept in this question lies in distinguishing between **platelet quantity** and **platelet quality**. 1. **Why Option B is correct:** The question specifies a "platelet function defect" (qualitative defect). In such conditions (e.g., Glanzmann thrombasthenia or Bernard-Soulier syndrome), the bone marrow produces a sufficient number of platelets, so the **platelet count remains normal**. However, because these platelets cannot adhere or aggregate properly to form a primary hemostatic plug, the **Bleeding Time (BT) is increased**. BT is the clinical gold standard for assessing platelet function and the formation of the primary platelet plug. 2. **Why the other options are incorrect:** * **Option A:** A normal BT would imply functional platelets, which contradicts the diagnosis of a function defect. * **Option C:** This describes **Thrombocytopenia** (quantitative defect). While BT would be increased here, the primary pathology in the question is functional, not numerical. * **Option D:** A decreased bleeding time is clinically rare and usually associated with hypercoagulable states, not bleeding disorders. **NEET-PG High-Yield Pearls:** * **Bleeding Time (BT):** Measures primary hemostasis (Platelets + Vessel wall). Normal: 2–7 minutes. * **Glanzmann Thrombasthenia:** Deficiency of **GPIIb/IIIa** (failure of aggregation). * **Bernard-Soulier Syndrome:** Deficiency of **GPIb** (failure of adhesion); characterized by **giant platelets** and mild thrombocytopenia. * **Von Willebrand Disease (vWD):** The most common inherited bleeding disorder; causes increased BT because vWF is required for platelet adhesion. * **Drug Alert:** Aspirin irreversibly inhibits COX-1, leading to a functional defect (increased BT) despite a normal platelet count.

Q: Anemia, splenomegaly, and structural defects are typically seen in which of the following conditions?

Thalassemia major. **Explanation:** **Thalassemia Major** (also known as Cooley’s Anemia) is the correct answer because it represents the most severe form of beta-thalassemia, characterized by a near-total lack of beta-globin chain synthesis. This leads to a triad of clinical features: 1. **Severe Anemia:** Ineffective erythropoiesis and hemolysis of defective red blood cells lead to profound microcytic hypochromic anemia, usually manifesting within the first 6–9 months of life. 2. **Splenomegaly:** Massive enlargement occurs due to both extramedullary hematopoiesis and the sequestration of damaged RBCs. 3. **Structural Defects:** To compensate for chronic anemia, the bone marrow undergoes massive expansion. This results in characteristic skeletal changes such as **"Chipmunk facies"** (prominent maxilla, malocclusion of teeth) and a **"Hair-on-end"** appearance on skull X-rays. **Incorrect Options:** * **Thalassemia Minor:** Usually asymptomatic or presents with mild anemia. Patients do not exhibit significant splenomegaly or skeletal deformities. * **Mediterranean Anemia:** This is a historical synonym for Thalassemia. However, in the context of this question, "Thalassemia Major" is the specific clinical entity that defines the severe phenotype described. * **Polycythemia:** This condition involves an *increase* in red blood cell mass, which is the physiological opposite of anemia. **NEET-PG High-Yield Pearls:** * **Target Cells:** Commonly seen on peripheral smears of Thalassemia patients. * **Mentzer Index:** (MCV/RBC count) 13 suggests Iron Deficiency Anemia. * **Hb Electrophoresis:** In Thalassemia Major, there is a marked increase in **HbF** and absence/reduction of HbA. * **Iron Overload:** The primary cause of mortality in these patients (due to repeated transfusions), leading to restrictive cardiomyopathy and endocrinopathies.

Q: Examination of a lymph node from the neck of a 26-year-old man with bilateral cervical lymphadenopathy reveals total effacement of nodal architecture, and at higher power, the characteristic cell shown below. Which of the following additional studies is best suited for confirmation of diagnosis in this case?

Immunohistochemistry. ***Immunohistochemistry*** - **CD15** and **CD30** positivity is the **gold standard** for confirming **Hodgkin's lymphoma** with **Reed-Sternberg cells**, which show characteristic **owl's eye** appearance with large nucleoli. - **Immunohistochemistry** provides definitive identification of the **Reed-Sternberg cell phenotype** and distinguishes it from other large cell lymphomas through specific marker expression. *Serum protein electrophoresis* - Used primarily to detect **monoclonal gammopathy** and **multiple myeloma** through identification of **M-protein** spikes. - Not specific for **lymphoma diagnosis** and cannot identify the characteristic **Reed-Sternberg cell** markers needed for Hodgkin's lymphoma confirmation. *Flow cytometry* - **Reed-Sternberg cells** are typically **too large** and **fragile** to be effectively analyzed by flow cytometry, often getting lost during sample preparation. - More suitable for **B-cell** and **T-cell lymphomas** where smaller, intact lymphocytes can be analyzed for surface markers. *Gene rearrangement studies* - Primarily used to detect **clonal B-cell** or **T-cell populations** in **non-Hodgkin lymphomas** through **immunoglobulin** or **T-cell receptor** gene rearrangements. - **Hodgkin's lymphoma** diagnosis relies on **morphology** and **immunophenotype** rather than specific gene rearrangement patterns.

Q: A 28-year-old woman with sickle cell anemia marries a 31-year-old man with no abnormality. What are the respective probabilities of having (i) sickle cell disease and (ii) sickle cell trait in their offspring?

0% and 100%. ### Explanation **1. Understanding the Genetics (The Correct Answer)** Sickle cell anemia is an **autosomal recessive** disorder [1]. To determine the offspring's risk, we must identify the parental genotypes: * **Mother:** Has sickle cell disease (SCD), meaning her genotype is **SS** [1]. * **Father:** Has no abnormality (Normal), meaning his genotype is **AA**. Using a Punnett square for an **SS × AA** cross: * All possible offspring will receive an 'S' allele from the mother and an 'A' allele from the father. * **Genotype of all offspring:** **AS** (Sickle Cell Trait). * **Probability of Disease (SS):** 0% * **Probability of Trait (AS):** 100% **2. Why Other Options are Incorrect** * **Option B (25% and 50%):** This occurs in a cross between two carriers (**AS × AS**). In that case, there is a 25% chance of SS, 50% chance of AS, and 25% chance of AA. * **Option C (50% and 25%):** This does not follow standard Mendelian inheritance patterns for a single-gene recessive trait. * **Option D (25% and 25%):** This distribution is incorrect for any combination of these specific parental genotypes. **3. NEET-PG High-Yield Clinical Pearls** * **Molecular Basis:** A point mutation (missense) in the β-globin gene on **Chromosome 11**, where **Glutamic acid** is replaced by **Valine** at the 6th position [1]. * **Sickle Cell Trait (AS):** Usually asymptomatic but provides a selective advantage against *Plasmodium falciparum* malaria [1]. * **Screening:** Solubility tests (e.g., Sodium dithionite) are used for screening, while **Hb Electrophoresis** or HPLC is the gold standard for diagnosis. * **Metabisulfite Test:** Induces sickling in both trait (AS) and disease (SS) by reducing oxygen tension [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 598-599.

Q: A 48-year-old man complains of weakness and easy fatigability for 6 weeks. He has worked for 20 years in a chemical factory that produces a variety of plastics and other synthetic compounds. A complete blood count shows a hemoglobin level of 8.2 g/dL, WBC count of 45,000/mL, and a platelet count of 40,000/mL. Examination of a bone marrow aspirate reveals numerous malignant myeloblasts, and a diagnosis of acute myeloid leukemia is made. Exposure to which of the following agents is the most likely cause of this patient's hematologic disease?

Benzene. **Explanation:** The correct answer is **Benzene**. This patient presents with clinical and laboratory features of **Acute Myeloid Leukemia (AML)**, characterized by anemia, thrombocytopenia, and a high blast count. [1] **1. Why Benzene is Correct:** Benzene is a well-established occupational leukemogen. It is a volatile organic compound used extensively in the production of plastics, resins, synthetic fibers, rubber, and dyes. Chronic exposure leads to bone marrow toxicity through its metabolites (like hydroquinone and catechol), which cause DNA damage and chromosomal aberrations (specifically deletions of chromosomes 5 and 7). This typically manifests first as aplastic anemia or myelodysplastic syndrome (MDS), which frequently progresses to AML. **2. Why the Other Options are Incorrect:** * **Benzopyrene:** A polycyclic aromatic hydrocarbon found in cigarette smoke and coal tar; it is primarily associated with **lung cancer** and skin cancer, not leukemia. * **Carbon tetrachloride:** Historically used as a solvent and refrigerant; it is a potent hepatotoxin causing **centrilobular necrosis** and fatty change in the liver, but it is not a primary cause of AML. * **Glycerin:** A simple polyol compound used in food and pharmaceutical industries; it is non-toxic and has no known carcinogenic or leukemogenic properties. **Clinical Pearls for NEET-PG:** * **Occupational Risk:** Besides benzene, exposure to **ionizing radiation** and **alkylating agents** (e.g., Busulfan, Melphalan) are major risk factors for secondary AML. * **Chromosomal Link:** Benzene-induced AML is often associated with **monosomy 5 or 7**. [2] * **Key Association:** Always suspect benzene exposure in patients working in the **rubber, petroleum, or printing industries** presenting with pancytopenia or leukemia.

Q: Which gene mutation in AML is associated with a good prognosis, rather than a poor prognosis?

NPM1. **Explanation:** In Acute Myeloid Leukemia (AML), cytogenetic and molecular markers are the most important predictors of treatment outcome and overall survival [1]. **Why NPM1 is Correct:** The **NPM1 (Nucleophosmin 1)** mutation is one of the most common genetic alterations in AML (found in ~30% of cases). When it occurs in the **absence of an FLT3-ITD mutation**, it is associated with a high rate of complete remission (CR) and favorable overall survival. It is typically seen in AML with normal cytogenetics and is now recognized as a distinct entity in the WHO classification [1]. **Analysis of Incorrect Options:** * **A. FLT3 gene:** Mutations in *FLT3* (especially Internal Tandem Duplications or **FLT3-ITD**) are associated with a **poor prognosis**, high relapse rates, and shorter survival. * **B. WT-1:** Overexpression or mutation of the **Wilms Tumor 1 (WT-1)** gene is generally considered a marker of **poor prognosis** and is often used to monitor minimal residual disease (MRD). * **D. MLL (KMT2A):** Rearrangements of the **Mixed Lineage Leukemia (MLL)** gene (chromosome 11q23) are associated with an **adverse/poor prognosis** and are frequently seen in therapy-related AML [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Favorable Prognosis Markers:** *NPM1* (without FLT3), *CEBPA* (double mutation), and core-binding factor leukemias [t(8;21) and inv(16)] [1]. * **Poor Prognosis Markers:** *FLT3-ITD*, *TP53* mutations, *ASXL1*, and complex karyotypes (≥3 chromosomal abnormalities) [1]. * **NPM1 Morphology:** Often associated with "cup-shaped" nuclear invaginations in blasts. * **Treatment Note:** Midostaurin is a multi-kinase inhibitor added to chemotherapy specifically for *FLT3*-mutated AML.

Q: A 33-year-old man has experienced multiple nosebleeds along with bleeding gums for the past month. On examination, his temperature is 37.3deg C. He has multiple cutaneous ecchymoses. Laboratory studies show hemoglobin, 8.5 g/dL; hematocrit, 25.7%; platelet count, 13,000/mm3; and WBC count, 52,100/mm3 with 5% segmented neutrophils, 5% bands, 2% myelocytes, 83% blasts, 3% lymphocytes, and 2% monocytes. Examination of his peripheral blood smear shows the blasts have delicate nuclear chromatin along with fine cytoplasmic azurophilic granules. These blasts are CD33+. Which of the following morphologic findings is most likely to be present on his peripheral blood smear?

Auer rods. The clinical presentation of a young adult with **pancytopenia** (anemia, thrombocytopenia, and neutropenia) despite a high total WBC count, combined with a high percentage of **blasts (83%)**, is diagnostic of **Acute Leukemia** [1]. **1. Why Auer Rods are correct:** The presence of **fine cytoplasmic azurophilic granules** and the expression of **CD33** (a myeloid marker) confirm the diagnosis of **Acute Myeloid Leukemia (AML)**. **Auer rods** are pathognomonic for AML. They are needle-like, pink/red inclusions in the cytoplasm of myeloblasts formed by the fusion of primary azurophilic granules (lysosomes) containing peroxidase. **2. Why the other options are incorrect:** * **Dohle bodies:** These are light blue-gray, oval inclusions in the periphery of neutrophils seen in **leukemoid reactions**, infections, or burns. They represent remnants of rough endoplasmic reticulum. * **Hairy projections:** These are characteristic of **Hairy Cell Leukemia**, a mature B-cell neoplasm. Patients typically present with massive splenomegaly and "dry tap" on bone marrow aspiration, not acute blast crises. * **Heinz bodies:** These are inclusions of denatured hemoglobin seen in **G6PD deficiency** or unstable hemoglobinopathies. They require supra-vital staining (like Crystal Violet) to be visualized. ### NEET-PG High-Yield Pearls * **Auer Rods:** Pathognomonic for AML (specifically M1, M2, M3, and M4 subtypes). * **Faggot Cells:** Cells containing bundles of Auer rods, classically seen in **Acute Promyelocytic Leukemia (APL/M3)**. * **CD Markers:** CD13, CD33, and MPO (Myeloperoxidase) are the most specific markers for the myeloid lineage. * **Hyperleukocytosis:** A WBC count >50,000/mm³ (as seen here) increases the risk of leukostasis and DIC, especially in AML [2].

Question 1

A patient presents with bleeding due to platelet function defects. Which of the following features is typically observed?

Accepted Answer

Normal platelet count and increased bleeding time

Answer

Normal platelet count and normal bleeding time

Answer

Decreased platelet count and increased bleeding time

Answer

Normal platelet count and decreased bleeding time

Question 2

Anemia, splenomegaly, and structural defects are typically seen in which of the following conditions?

Accepted Answer

Thalassemia major

Answer

Thalassemia minor

Answer

Mediterranean anemia

Answer

Polycythemia

Question 3

Examination of a lymph node from the neck of a 26-year-old man with bilateral cervical lymphadenopathy reveals total effacement of nodal architecture, and at higher power, the characteristic cell shown below. Which of the following additional studies is best suited for confirmation of diagnosis in this case?

Accepted Answer

Immunohistochemistry

Answer

Serum protein electrophoresis

Answer

Flow cytometry

Answer

Gene rearrangement studies

Question 4

A 28-year-old woman with sickle cell anemia marries a 31-year-old man with no abnormality. What are the respective probabilities of having (i) sickle cell disease and (ii) sickle cell trait in their offspring?

Accepted Answer

0% and 100%

Answer

25% and 50%

Answer

50% and 25%

Answer

25% and 25%

Question 5

If both parents have sickle cell anemia, what is the likelihood of their offspring inheriting the disease?

Accepted Answer

100%

Answer

10%

Answer

25%

Answer

50%

Question 6

A 48-year-old man complains of weakness and easy fatigability for 6 weeks. He has worked for 20 years in a chemical factory that produces a variety of plastics and other synthetic compounds. A complete blood count shows a hemoglobin level of 8.2 g/dL, WBC count of 45,000/mL, and a platelet count of 40,000/mL. Examination of a bone marrow aspirate reveals numerous malignant myeloblasts, and a diagnosis of acute myeloid leukemia is made. Exposure to which of the following agents is the most likely cause of this patient's hematologic disease?

Accepted Answer

Benzene

Answer

Benzopyrene

Answer

Carbon tetrachloride

Answer

Glycerin

Question 7

A patient presents with increased aPTT and PT but no bleeding tendency. This was also noted during surgery where no increased bleeding occurred. Which coagulation factor is deficient?

Accepted Answer

Factor V

Answer

Factor VII

Answer

Factor X

Answer

Factor XI

Question 8

Which gene mutation in AML is associated with a good prognosis, rather than a poor prognosis?

Accepted Answer

NPM1

Answer

FLT3 gene

Answer

WT-1

Answer

MLL

Question 9

Sezary syndrome is classified under which of the following categories?

Accepted Answer

T cell leukemia

Answer

Lymphoma

Answer

B cell leukemia

Answer

Pigmented disorder of skin

Question 10

A 33-year-old man has experienced multiple nosebleeds along with bleeding gums for the past month. On examination, his temperature is 37.3deg C. He has multiple cutaneous ecchymoses. Laboratory studies show hemoglobin, 8.5 g/dL; hematocrit, 25.7%; platelet count, 13,000/mm3; and WBC count, 52,100/mm3 with 5% segmented neutrophils, 5% bands, 2% myelocytes, 83% blasts, 3% lymphocytes, and 2% monocytes. Examination of his peripheral blood smear shows the blasts have delicate nuclear chromatin along with fine cytoplasmic azurophilic granules. These blasts are CD33+. Which of the following morphologic findings is most likely to be present on his peripheral blood smear?

Accepted Answer

Auer rods

Answer

Dohle bodies

Answer

Hairy projections

Answer

Heinz bodies

Hematopathology — MCQs

Hematopathology — MCQs

On this page

Practice by Chapter

Want unlimited practice?